Granuels receives approval for Penicillamine Capsules

Source

Team Infinities:

Granuels India Limited, NSE Symbol: GRANULES, BSE Script Code: 532482, gets approval Penicillamine Capsules USP, 250 mg from the US Food & Drug Administration (US FDA). It is bioequivalent to the reference listed drug product (RLD), Cuprimine of Bausch Health Americas, Inc. The product would be manufactured at Granules manufacturing facility in Chantilly, Virginia and is expected to be launched shortly.

Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Add new comment

Comment Editor

  • No HTML tags allowed.